In a landmark FDA ruling in March 2017, Ocrevus became the first disease-modifying therapy (DMT) approved for the treatment of primary-progressive multiple sclerosis (PP-MS). Although the drug’s efficacy appears more modest in this population than in patients with relapsing forms of MS, the combination of proven clinical benefits and a positive safety profile (to date) yields a highly compelling product for a deeply underserved population. Even so, questions remain about exactly how it will fit into the progressive MS treatment algorithm. DRG’s launch tracking series will examine how the perception and performance of Ocrevus has evolved through Year 1 with an MS prescriber base that has hitherto struggled to treat PP-MS.
Emerging Therapies is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and use of the launched product as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
Markets covered: United States.
Primary research: Survey of approximately 75 U.S. neurologists.
Key metrics included: